Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 4/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.35 |
| ▸ | CDK2 | P24941 | 5/20 | 0.35 |
| ▸ | MARK3 | P27448 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.32 |
| ▸ | LCAT | P04180 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748962 | 0.85 | LIPE (0.38) | LIPECCNE1CDK2MARK3ACACB | |
| SCHEMBL30748954 | 0.84 | CDK2 (0.37) | CCNE1CDK2ACACB | |
| SCHEMBL30749098 | 0.82 | CCNE1 (0.36) | CCNE1CDK2ACACBLCATP2RX3 | |
| SCHEMBL30748908 | 0.82 | ACACB (0.37) | CCNE1CDK2ACACBLCATP2RX3 | |
| SCHEMBL30749047 | 0.78 | CCNE1 (0.38) | CCNE1CDK2MARK3ALDH1A1 | |
| SCHEMBL30749006 | 0.76 | EGLN1 (0.44) | CCNE1CDK2MARK3ALDH1A1 | |
| SCHEMBL30748793 | 0.76 | CDK2 (0.37) | CCNE1CDK2 | |
| SCHEMBL30748774 | 0.75 | HTT (0.40) | CCNE1CDK2ALDH1A1 | |
| SCHEMBL30748888 | 0.75 | CCNE1 (0.39) | CCNE1CDK2ALDH1A1 | |
| SCHEMBL30749138 | 0.73 | CDK2 (0.40) | CCNE1CDK2MARK3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | LIPE 983/4885CCNE1 2310/4885CDK2 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.